|
1. Gerovital-H3,
its regenerative effects
2. Gerovital-H3, anti-depressant effects
3. Gerovital-H3,
creator Ana Aslan's life
4. Gerovital-H3, treatment in osteoarthritis
5. Old
age humoral dismetabolism (GH-3)
6. Gerovital-H3
treatment in rheumatology
7. Gerovital-H3
- classic antiaging medicine
.
Dr. Ana Aslan and Gerovital-H3
by Mircea Dumitru M.D. Ph.D. (Ana Aslans personal physician).
Who was Ana Aslan?
to order
Ana Aslan is renowned for her essential
contribution to gerontological research as well as for having patterned the best geriatric
treatment influencing the aging process. Ana Aslan was the first person to rule out the
fatalistic approach to aging, providing a new method in gerontology by opening the way to
the prevention and treatment of old age.
I worked with Professor Ana Aslan for 25
years, from 1963, first as a researcher, then as chief physician and afterwards as the
Director of the National Institute of Gerontology and Geriatrics in Bucharest, Romania,
between 1978 and 1990.
In the last 3 years of her life, Aslan
chose me as her personal physician and three months before her death she asked me to do
some personal things, including to write a book about her life and her work. So I took
notes at her bedside as a moral testament.
In addition to her life, she talked of her
views of politics, religion, euthanasia, dying, death and love. As such I had the
opportunity to know her private thoughts and personal thinking.
On her 90th solemn birthday celebration at
the Romanian Academy in Bucharest on May 22nd, 1987, on behalf of the Romanian National
Institute of Gerontology and Geriatrics, I said; "I want to express my emotion and
say how difficult it is to talk about Ana Aslan, being such a complex personality, the
story of Gerontology might as well be the story of Aslan."
"Ana Aslans life can be seen in
her work. She has battled courageous fights, all for the service of good, to make
mans dream to live with dignity for as long as possible. Now we celebrate the
inventor, the scientist, the physician, and the professor. For 35 years since 1952, she
has led us as the first Institute of Gerontology in the world. Ana Aslan is the Ambassador
of Gerontology and a brilliant woman. As a scientist she is an inventor, not an imitator.
She has played such an important role in Gerontology at the world level. She has given the
world decades of research that revealed that Gerovital-H3 is the most effective treatment
in geriatrics. Ana Aslan is the original contributor in the basic research concerning
cellular and molecular aging, and researching her product reaction in the body. She has a
special empathy for the elderly and has always fought to improve their condition all over
the world. She worked with others to initiate the General Assembly of the United Nations
Organization on aging, held in Vienna, 1983. Aslan has a remarkable understanding and
appreciation for beauty and culture. At one time she visited Hippocrates grave and on
which she stated, "I now realize how small I am."
As a disciple and collaborator, and being
inspired by the University Hymn, I declare "Viva Academia! Viva Professores! Viva Ana
Aslan!"
Aslans distinctions
1. Commander of the order "Meritor
Della Republica," Italy, 1969
2. Commemorative Gold Medal, Nicaragua, 1971.
3. Cross of Merit, first class Order of Merit, Germany, 1971.
4. Hero of Socialist Labor, Romania, 1971.
5. "Augusto Pinaud," Medal, Venezuela, 1972.
6. Cavalier de la Nouvelle Europe, Prize Oscar, Italy, 1973.
7. Knight of the Order "Les Palmes Academiques," France, 1974.
8. International Prize, "Eva," Italy, 1974.
9. Commander of the Order "De Orange Nassau," Holland, 1975.
10. "LOrdre du Merite," Grande Officier, Senegal, 1976.
11. "Dag Hamarskjoeld," International Prize, Italy, 1977.
12. "Dama di Collare Del Santo Graal," Nice, 1978 (granted by Italy)
13. Honorary Foreign Citizen and Honorary Professor of Sciences, Manila,
Philippines, 1978.
14. President and Honorary Guest of the Symposium, "Ageing Comes of Age,"
Philippines Academy, Philippines Association of Geriatrics and
Gerontology, 1978.
15. Officer of the Order "Merito Della Republica Italiana," 1979.
16. La Medaille et le Prix "Leon Bernard" La 35eme Assemblee Mondiale de
la Sante, 1982.
Aslan is quoted in the
following
-
Whos Who in America (1972)
-
Whos Who in the World (1971)
-
Whos Who of Women (1971)
-
British Encyclopaedia (1974)
-
Whos Who of Intellectuals (1976)
-
The International Men of Achievement (1976)
-
International Biographical Association of England (1978)
Dr. Dumitru comments
We are witnessing a spectacular alteration
of the age pyramid. Furthermore the process of the demographic aging of the population
will continue to increase in the coming decades.
I feel obliged to sound an alarm at the
apparition of this phenomenon unique in human history, at least in relation to how the
appropriate tactics and strategies should be adopted.
Human society has the duty to benefit in an
organised way from the knowledge, experience, wisdom and the free time of the elderly.
Activity, as a way of life for aging and
aged people, creates for them a mental and physical well being, changing old age into a
useful period, not only at the individual and family level, but at the social level too.
The traditional image of the elderly
incapable of working, needing help, care and with a tendency for solitude is being
re-evaluated. Elderly people do not appear as a homogenous category of population, but as
a very heterogeneous one, from the demographic, medical and social standpoint.
The concept of the "elderly" from
the social standpoint is becoming outworn and out-of-fashion, and is frequently considered
in a merely functional sense related to the elderlys capacity of assuming a role in
the community.
Interdisciplinary researches are apt to
offer solutions for promoting an Active Old Age. As a supporter of an optimistic
conception of the third age, in the data that I am submitting, I will propose measures to
forming a new attitude towards this last stage of life.
"The everlasting ageless youth"
has always been one of the great desires and concerns of mankind. Especially in the latter
decades, if the thoughts of the last thousand years were put into a microscopic lens then
the complex equation of human aging would begin to reveal some of its unknown values,
however man cannot accept the idea of aging and death.
I have discussed the topics of aging and
old age with my patients during the last 40 years of my pregeriatric and geriatric
practice; these years having been dedicated to scientific research relating to the aging
diseases; their prevention and treatment.
I worked for 25 years at the National
Institute of Gerontology and Geriatrics in Bucharest, of which I was the Director and the
closest co-worker of the famous Romanian physician- Ana Aslan for 11 years. I have had the
opportunity to examine patients of different ages from all over the world, to know their
thoughts, their concerns and their varied questions. For example, Ive talked with
many young people, for whom aging, death and disease were states, which they hadnt
accepted yet as a possibility during their life. Other young people I have dealt with had
diseases and pain and wished an end as quickly as possible. Some considered that they
ought to try everything as soon as possible and had no respect for their health. Some
women believed the menopause was the starting of their old age and other healthy old
(often-centenarian) people who were in full activity pleaded for the beauty of this age
and regarded life from the height of their wisdom. Of course there were also their
children abandoned those elderly who had severe chronic diseases and were living alone
having. All this has been a fantastic lesson for my pregeriatric and geriatric practice.
But only fate made me the personal
physician of Professor Ana Aslan during the last three years of her life. During this time
we became closer in spirit and in our long conversations she shared many of her private
thoughts of her life experience fighting against old age and its sufferings.
Asking her many questions that I was
concerned about gave me the opportunity to learn the convictions of one of the most famous
personalities in the world, her ideas were pioneering in the fascinating field of
Gerontology and Geriatrics.
In the afternoons and in the evenings on
the terrace of her apartment at the Otopeni Clinic, (where she was convalescing), she told
me her thoughts, and interrupted only by nightingale trills, she talked of the 84
countries she had visited. The people, their cultures, the famous personalities shed
met, and normally, about the history of her only son- Gerovital-H3- the product that could
improve the quality of life.
After 40 years of age (which is a critical
period from a biological point of view), many people begin to ask; "What is old age?
What about the aging process? How can we fight against it? Can old age be delayed or
prevented? What are the factors accelerating the aging process? Should we learn to die?
Has a person the right to dispose of his or her own life and decide when the end is to be?
What about sexual activity in old age? Can it be improved? How will relations between the
generations be affected? What is the older persons role in society and family?" and
so on.
My understanding of the concerns of
gerontology schools in the United States, Great Britain, Germany, France and Romania
regarding the "Life Extension Research" and from my geriatric practice, in time,
I appreciated that "those good habits" give strength and active life in aging.
Today we have discovered what was
originally thought to be a compulsory condition of old age, namely the presence of heart
disease, arthritis, diabetes, depression. Presently and especially in the near future
these are (and will) no longer are the facts of aging.
Everything depends on the way you live from
birth to death and what kind of supplements you are taking.
The behaviour is based on the way of
thinking to remain young, on the strategy to fight against gaining weight, to prevent
paralysis, to fight against the stress and to maintain a young at heart spirit.
In the following pages, I will try to
answer some of these questions and to draw the way to live, remain active and to retain
dignity in older age.
"To grow old in a beautiful and
dignified way is at the same time a science and an art." Ana Aslan.Ana Aslan.
The aging process and old age
Ana Aslan remembered with pleasure a
question asked by many reporters and research workers; "What made you in the
1940s- when very few people thought about geriatrics- dedicate yourself to the study
of aging and to the care of old people?"
Ana Aslans answer was always full of
nostalgia; "At the age of 50 I changed my career and I started another life dedicated
to Geriatrics. I was a specialist in Internal Medicine and Cardiology and in 1945 on
January 1st, I received a congratulation card, which I keep with my precious possessions.
This card was signed by many of my patients who wrote- On the occasion of your birthday
a group of old patients, some of lifes broken toys, wish you good health and many
happy years! - I read and re-read- these words many times and they continued to stir
me and even to obsess me. I told myself, that in fact, these broken toys could be mended,
and I wondered what help I could give old people? Those words and that card, together with
the impulse given by one of my professors, were the seed which sprang in my mind and
made me dedicate the rest of my life to the study and treatment of old people. It was the
elderly showed me that TIME is the killer of organic substance and it puts its definite
imprint on the human organism."
In our contemporary society, we are
witnessing two essential tendencies, the aging population and the technical progress.
The understanding of demographic
tendencies, therapy and recovery from the diseases of old age are priority problems with
economical, political and social implications.
Each of us is a witness to a spectacular
increase of the average life span, which increased from 40-50 years in the last century,
and now, to more than 78 years old. Grandfathers take care of their grandchildren, and
their great grandchildren, and they share with them their life experience, a feat not
possible before in the history of mankind.
In the year 2000 those over 60 years old
will represent 15-20% of the total population of the earth. The rate of those over 65
increased from 200 millions in 1950s to 400 millions in 1985, and to an estimated
600 millions in 2000, and to more than 1 billion in 2025!
What are the implications of the presence
of such a segment of elderly within the population? Should they stay outside of the normal
social life? The answer to these questions has an impact not only on Gerontology, but in
philosophy, religion, politics and economy too.
Geriatrics deals with the medicine for the
elderly, and Gerontology studies the modifications of the human organism in time, as such
Gerontology can define the aging process and can distinguish between aging and disease.
Alone they cannot answer and solve the fundamental aging questions, but together they
become a powerful science.
Aging is a plurality of normal
changes of mankind due to the lapse of time, the change in the frame of mind and in the
physical condition of each of us.
Disease is an accident, a
pathological process, abnormal, which can occur occasionally in childhood, adulthood and
is not compulsory in old people.
Disease can be prevented, treated, or if it
becomes chronic it can be alleviated. Disease can also often hide aging and for this
reason we should pay attention to the change due to time "per se."
The aging process is suggestively
illustrated in Figure 4. It shows the increasing presence of aging from the period of
embryo, childhood, adulthood and into old age.
In this conception, old age is the last
period of the life, when the aging signs become evident; signs such as the gerontoxon (or
arcus senilis), a degenerative change in the cornea occurring in persons over the age of
50 and the ceasing of the menstrual cycle etc.
For the reader it is very important to know
that aging is subjected to the influence of genetic and environmental factors. Under the
influence of these factors, the aging rhythm can be normal, accelerated, or delayed.
Each person has his or her own biological
clock, which can function normally, or it may have an accelerated or delayed function.
The nutrition, physical, environmental
factors, way of life, presence or absence of diseases, stress and the eutrophic treatment
with Gerovital-H3 influences the aging rhythm.
After the age of 40, the proportion between
muscular and fat tissue changes. Around the age of 60- 30% of the muscular mass is
replaced by fat tissue. The articular flexibility, muscular strength, pulmonar
ventilation, vascular elasticity and cardiac efficiency decrease with advancing age.
Visual acuity and ovarian function are
among the first changes, which announce the period of senescence. In bone structure,
important changes take place, which should be prevented with the necessary steps.
At the age of 65 we can no longer do what
we did at the age of 30 and this fact we all understand.
Old age is often a "state of
mind" and the human spirit is the strongest treatment, which should be fed with
understanding, useful constructive work, love, tolerance, kindness and friendship.
Old age can be a period of pain, loneliness
and disease, with high medical cost and social complexity; Grieg described it as
"diminishing also has its beauty," Juvenal however, said, "old age is worse
than death."
In everyday life, in literature, in fairy
tales, old age aureole is not missing. In popular wisdom, the old man appears as a
positive character, kind and clever. The elderly are capable of useful activities for
themselves and for others, they can solve difficult situations, to value their creativity.
They are a treasure of wisdom and preserve a "living history," they are the
keepers of history, and by vocation, character and inspired choice, become as much
important as inventors.
When I asked Aslan, "what is aging and
old age and how do we fight it?" she answered,
"Old age is full of suffering and pain
and I regard this as a parasite of life which develops slowly and whether you know it or
not, it takes hold of us. From the age of 50 onward, I declared war on aging and old age.
Gerontology and Geriatrics have enough possibilities to slow down the aging process and to
delay old age onset. We are obliged to guard against and to explain to healthy or sick
patients, what it means to grow old, and what they have to do in order to extend their
life in conditions of quality. My treatment and my method is a solution, Gerovital-H3 is
not only a treatment, it is hope, and when there is no hope, there is nothing."
Ana Aslans incredible adventure
(IN HER OWN WORDS) "I accepted
that I had to leave Bucharest in order to be by myself. This was not easy for me, but in
those years, the air that I was breathing was not enough. Brilliant lights are attractive
to creative spirits, but they can also deprive you of sight. The magnificent oaks have too
much shade, and under their magnificent crown you can find the smallest trees. Their seeds
should be taken by the wind to fertile places."
Ana Aslan had many personal ideas, one of
which was to start a medical school in Timisoara, the western Romanian town situated on
the banks of the Bega channel.
It was here that she met Dr. Pius Branzeu,
a student under the famous Professor Loriche. She discussed his methods of Novocain
treatments on post-operative incisions and later learned about Dos Ghalis method of
intravenous administration of Novocain in patients with bronchial asthma.
Ana Aslan passionately studied Professor
C.I. Parhons work as well. After 30 years of clinical and experimental observations,
Parhon reached the conclusion that aging is a disease and that it can be treated. In 1908
he published his observations of two cases of senile ostemalacia and in 1925, he
introduced the term Ilikibiology, meaning morphological, chemical and physiological
variations related to age.
"I taught at the medical clinic in
Timisoara and learned the basic notions of gerontology. I read all the works of Marinescu,
Parhon, Metchnikoff, Charcot and Burger (the principle disciples of gerontology) and I
also maintained a relationship with Dr. Parhon. Since 1946, he was the Director of the
Institute of Endocrinology in Bucharest and the chair of the Endocrinology Department of
the University there. I returned to Bucharest once a month just to talk to him."
"Parhon was a pioneer in gerontology.
He treated aging patients with extracts of epiphysis, gonads, insulin and vitamin E, in
1909 he published the first book in the world of endocrinology and in 1955 published the
book Biology of Ages, which was translated all over the world."
"Parhon had a universal mind and was a
wonderful man. Our privileged relationship was in the field of gerontology; this was where
his heart was. He believed in rejuvenating and ardently maintained that life cannot be
only a one-way direction. He knew everything, botany, zoology, endocrinology, psychiatry
and anthropology. His mind was like an encyclopaedia! Above all, Parhon was a man of great
generosity and dedication. He sacrificed many things for medicine, even including some
family relationships, he was quite different from Danielopolu but without the two, I would
not be what I am now!"
In 1946, Aslan published her first research
on Novocain, The Novocain Action on the Respiratory Rate when injected in the Human.
"After the first results with Novocain injections in the vascular embolias, I tried
this treatment on patients with arthosis and those with a tendency to ankylosis. Because
these diseases are chronic, I administered each with more injections. With great joy, I
noticed an improvement in the local symptoms, and even more importantly, a great
improvement in their overall general condition. Before the treatments, the patients
avoided any movement due to pain, and then they were willing and wanting to walk, sit up
and read, and talk. The biggest reward was to notice an increase in their interest in life
and for their families."
"These improvements also came along
with much more restful sleep for the patients. This led me to the hypothesis on
Novocains general effect on the neurophysical system. Maybe it had effects here as
well as locally. I noted these observations for two years until I could test my
hypothesis."
"On April 15, 1949, a GI Medical
student with arthrosis arrived in our clinic. For 3 weeks hed had terrible pains and
blocked articulation. I explained my idea about Novocain to him and after receiving his
permission, gave him an intra-arterial injection with 1% Novocain. His knee was mobile
immediately and he could flex his leg outright. What happiness! I administered this
treatment for another two weeks, after which he completely recovered."
"There was a nice park close to the
clinic in Timisoara, and one April afternoon while I was there I noticed an old man. He
was leaning on his crutches and when sitting down, he laid his head in his hands. I later
saw him in one of Van Goghs paintings! He embodied despair. My attention then turned
to an old couple who was walking with small steps, patiently leaning on one another. They
did not talk, but their dry wrinkled faces told enough about their many years. Their gait
was a symbol of their fraternity and support they have given, and will continue to give,
to each other for the rest of their lives."
"I then said to myself, why cant
I help these people? Why do they have to suffer such pain and suffering? If this young man
had started to walk after the injections I had given him, maybe these people could be
helped? They could smile again and regain their own sure steps."
"I did not go to Bucharest at the end
of the week as I had been doing on the weekends. Instead I returned to this park. All I
could focus on was old people. I was overwhelmed with age; I began to feel an unusual
sympathy. Something had touched me deep down, and I began my quest. At night I thought
about the Novocain shots Loriche had administered around wounds. If such rapid healing
occurred, couldnt it benefit these people as well? I became obsessed."
"After doing pharmacodynamic research
in 1946 with Dr. Danielopolu, this conviction crystallised in my mind between 1947-1949. I
was using Novocain to treat bronchial asthma according to Dos Gahalis method and to
treat arthritis and emboias according to Loriches method."
"I practically ran to Bucharest with
my results! Dr. Danielopolu advised me to share this with Parhon immediately. His words to
me were, "Novocain has an effect on aging. You should carefully carry out
this research. Come back to Bucharest and lead our Experimental Department here. Ill
make all the arrangements, just say youll come." I agreed and in a few
months I was back in Bucharest."
This adventure that began in Timisoara
continued in Bucharest. But it was here that the struggle really began. In order to clear
up the Novocain mechanism of action in arthritis, Aslan followed its effects on
experimental arthritis induced by formaldehyde (according to Seyle-Brownlees
method).
"In the fall of 1949, I wanted to
present my first observations to the Academy of Medicine. It was then that I realised the
envy-taking place among my colleagues, and how it was increasing. In a chorus, Milcu,
Lupu, Nicolau and Benetato were adamantly against it. "You need at least 25 cases"
they argued. Finally, they refused to include my research in the agenda being set for the
Academys meetings. It doesnt matter, I told myself, Alzheimer presented his
observations on a single case, and Hodgkin on only six!"
"After Parhon left the Institute of
Endocrinology, those that followed caused me much frustration. (They did, however, do one
good thing, for which I want to thank them, they agreed with my resignation and return to
Bucharest)."
"With the passing of time I learned
that the opposition made me more and more ambitious. I knew that I was right and I had to
prove it. Life would be too dull without controversy, and in my case, unfortunately, the
controversies overstepped the bounds of academic dispute. All of this doesnt matter
now, I forgave them many years ago."
"It was the co-operation with Parhon
that does matter. He was very good to me and was convinced by the results I was obtaining.
He was my moral support, and it is because of him that I continued with my research."
As soon as Aslan began publishing and
sharing her method, more and more people, most of them ill, started to visit the
Institute. The Institute, situated in an anonymous place, gradually became the Mecca of
the ill.
Scientists came to learn from her as well
as to undergo treatment. Some remained perplexed, listening to the testimonies of the old
people who had regained the joy of life, returned to their favourite activities, found
peace in their battles with insomnia. More importantly, they found their place in society,
a society who before had alienated and repulsed by them. Their spoken and written words
are proof of the effectiveness of her treatment, method and product, Gerovital-H3, which
had bought so much relief and hope to the suffering.
Many physicians came to the Institute for
training in gerontology and geriatrics, and to learn Aslans method. In return, Aslan
visited them in their countries to acknowledge and celebrate their results. With special
appreciation, she remembered Dr. Marion Bucker Bode of Germany. Besides leading a center
of geriatrics, she also had serious concerns for research. She talked also of Dr. Pop
Michel of Cyprus, these and many others, were considered her disciples in the fight
against aging.
Some of the many testimonials
After visiting the Institute in September
of 1958, Academician R. Bacov, Director of the Pavlov Institute in Moscow, wrote, "I
found the activity carried out at the Institute of Professor Aslan to be very interesting.
The problem they focus on fascinates the world. I think Professor Aslan has found a real
way to maintain the activity of the nervous system and to prolong the normal functioning
of the entire organism. I myself am convinced that Aslans method is a success. Thank
you for the wonderful demonstration of your results."
Robert A. Homes, M.D., chief physician in a
hospital in Washington D.C., confessed that he learned much from Aslans
revolutionary treatment. Hollings E., Senator S.C., Washington D.C., expressed his
admiration for a real mother nature, as well as Senator Howard W. of Nevada, who
remarked on the wonderful work in such an important field.
Professor Aslan thoroughly studied and
diversified the research, a fact that was noted in the pharmacology department of Harvard
University as well.
These were world-wide acknowledgements, the
Minister of Health in Belgium, Nameche Louis, stated that he was "impressed by the
social action developed by Aslan and convinced of the prophylactic results."
Ever since 1966, Lord Amulree of London
appreciated "the work Aslan developed in order to cover all of Romania with a network
of care centers for the elderly. These could very well be imitated by other countries and
I hope this wonderful work by Professor Aslan will be very wide spread."
Dr. Iderwal de Carvalbo, Professor of
psycho-pathology at the Sao-Paulo University in Brazil was "full of admiration for
all he saw and felt at the Institute when he personally noted the stateliness of
Aslans work and the magnificent results in treating aging with Gerovital-H3 and
Aslavital."
From the Institute of Geriatrics and
Gerontology of the University of Florence, Italy, Professor Francesco Antonini,
"admired the work carried out with such intelligence."
A letter of gratitude from Professor Mario
Giacorezzo from the Medical Clinic of Rome University, thanked Aslan "for this
masterly lesson."
Journalists, writers and poets whose
fantasy took them beyond the limits of reality soon visited the Institute seeing the
results in old patients. For example, Galina Seredrinkova wrote, "Fausts dream,
the alchemists fight for life has been solved by the well known woman of our century, Ana
Aslan. The gratitude and enthusiasm towards her talent and her deep scientific thinking
includes anybody between the walls of her institute."
A news journalist by the name of A. Umar,
considered Aslans results not only prestigious for Romania, but for the entire
world.
During her life, Aslan received thousands
of letters. They came from the most remote parts of the world. Sometimes the letters were
directed with no address, but a simple "Ana Aslan" on the envelope. The country
and address was not necessary, the entire world knew of her!
In most letters, patients expressed their
thanks, for regaining strength, hope and confidence. They expressed their gratitude for
her competence and devotion.
She had four secretaries who helped her
answer each and every one. They had a difficult job, working in the rhythm and time that
Aslan demanded. She did not consider this impressive correspondence as simple politeness
and responsiveness, but rather as a constitutive part of her own medical activity as a
doctor. The exchange with research institutes, such as the "Institute of Aging"
in the United States and in Kiev, meant contact.
From her travels and fame, Aslan made
friendships everywhere. Many of them became patients and followed her treatment for years
and years. One of these was Mr. Hans Matguart of Germany; he was a man of remarkable
culture, honour and honesty. After he learned of Aslans death (a month after she had
actually died), he took a plane to Bucharest. He went to her grave and quietly remained
there for some time, as homage and out of respect. He went on to address me; "It is a
pleasure for me to speak about Professor Ana Aslan, as she was, in my opinion, a world
authority and a remarkable person. My first encounter with her took place in 1982. Ana was
herself an old woman, but yet maintained all of her mental capacity. Her long medical
experience proved very useful. Ana was also being treated with Gerovital-H3. Her
intellectual capacity, maintained to the end of her life, is proof of the drugs
success."
"I had begun my treatment
(Aslans therapy) on August 12, 1980 and continued without an interruption. She
herself personally cared for me. She examined me and decided on which type of therapy. For
ten years, at regular intervals, I have been treated with Gerovital-H3 by injections and
by pills. I am now 76 years old; therefore I started therapy when I was 65. Since then, I
have continued leading negotiations in my field and making all the necessary decisions
about my activities. Would I still if I wasnt using Gerovital-H3? I definitely say
no!"
"In the last 10 years I have
accomplished my daily tasks with great joy. When we think that the normal man retires at
65 or earlier, then these 10 years are even more astonishing. I have held honorary
positions and been appointed several times as president of different organisations. This
activity is proof of my capacity. It should also be mentioned that in the last 10 years I
have also had no serious disease, more proof of healthy conditions due to Aslans
therapy."
"Throughout these 10 years I have
often talked with others in this long term treatment, and not once have I heard a negative
word. Of course this therapy cannot make miracles alone. Positive results only appear when
regular treatments are given and the physician one is dealing with is seen
regularly."
"Above all, I hope her knowledge will
be spread to all the people in this country and to all of human-kind."
During this visit, Mr. Matquart was
intrigued and puzzled about why her death had not been immediately announced. "Ana
belonged to mankind, not only to Romania. Surely, Belu cemetery would have been full with
people from all over the world?" But under communism, the people of Romania had no
possibility to taste and to know of Ana Aslans international success.
Biological basis of Gerovital-H3 treatment
Ana Aslan at the Institute of Gerontology
and Geriatrics in Bucharest, Romania experimented with Gerovital-H3 between 1951 and 1958.
Since 1951, Aslan stopped the use of hydrochloric-procaine; the research results
materialised a different product with a new formula- Gerovital-H3. In the new formula,
adding benzoic acid to procaine and inducing a greater access of procaine into the
hydrophobic cellular compartments modified the pharmacological action of
hydrochloric-procaine.
Between Gerovital-H3 and
hydrochloric-procaine there is a difference of pharmacological action. Hazard showed that
the procaine-based product has a stability of 6-months, whereas the Aslan product has a
much increased stability of 2 years and 6-months.
Once introduced into the human body, the
procaine molecule is hydrolysed by procainestherase into two metabolical fractions;
Paraaminobenzic acid (PABA) and Diethylaminoethanol (DEAE). The absorption of the two
metabolites is better when they result from the in-vivo hydrolysis of Gerovital-H3 than
administered as such. The absorption takes place in a competitive manner, which means that
the two metabolites compete for the active sites or mechanism that govern the absorption.
The DEAEs absorption is particular to the brain as compared to other organs.
The procaine from Gerovital-H3 has a
greater capacity of wadding the medium (pH), due to benzoic acid, reducing the degradation
speed of the product. DEAE splits into Ethanolamine, Glycine and Urea. Ethanolamine enters
the synthesis cycle of Choline and then acetylcholine.
In the case of Gerovital-H3, the
chromatographic techniques showed that there are intact procaine molecules in the blood
and heart of experimental animals 6 hours after the product was administered. There are
two possible explanations for the important difference in the procaine metabolism.
It is considered that hydrochloric-procaine
is differently metabolised depending on the pH of the solution. At a pH of 7, the procaine
is permeated "en mass" into the blood, but at a pH of 3.3 the procaine is
gradually set free from the blood.
An acid solution will decrease the sudden
release of the substance, a quality that Gerovital-H3 possesses. Cohen (1) shows that
benzoic acid will arrange itself in space in such a manner that it protects the procaine
molecule at its weak point from the action of procainestherasis. Important are also the K
ions, which amplify the procaine action at the level of the nervous, and the muscular
system (2). Gordon (3) has compared Gerovital-H3 and Procaine and found that there are
significant statistical differences in favour of Gerovital-H3. The experiments carried out
by Aslan (4) showed significant differences between Gerovital-H3 and Procaine inducing the
vascular conditioned and unconditioned reflexes in old patients.
Gerovital-H3 acts upon the human body both
under the form of an intact molecule and through the hydrolysis products PABA and DEAE,
which participate in the regulation of the intermediary metabolism.
Gerovital-H3 favours the acetylcholine
synthesis and it is a source of folic acid. In fact, a series of researches suggest the
hypothesis that procaine, by means of the PABA, can stimulate the intestinal flora and the
production of folic acid, vitamin K and tyramine.
The cellular effect of the Aslan product
bears different characteristics and dimensions regarding the organ in question and its
role within the body. The improvement of the superior nervous activity presents a
particular importance. Yau (4) made a pharmacological study upon Gerovital-H3 and
summarised its basic mechanism as,
Gerovital-H3 competitively and
reversibly inhibits monoamineoxidase (MAO).
Gerovital-H3 acts as an
antidepressive through the modification of the monoamine level in the brain.
Gerovital-H3 is very selective in the
oxidase desamination inhibition.
Gerovial-H3s oxidative
desamination of monoamine is done in such a way as to eliminate the hyper-blood-pressure
peak, so typically present after administering of other MAO inhibitors.
Gerovital-H3 is considered to play a
role in maintaing the physiogical status of the nervous cell membrane, restoring the
equilibrium between the processes of excitation and inhibition at the level of the
cortical and subcortical systems.
Gerovital-H3 exerts an important
regulatory action upon the nervous vegatative centers.
Further experiments reveal procaines
anabolic action. Studies on Infusoria (Colpidium colpoda and Vorticella) show the
proliferation of cells as a result of a weak procaine solution (6).
The investigations on rats drew the
attention of procaines anabolic affects improving the quality of the hair. Berger
obtained similar results with 6mg procaine/ Kg bodyweight in a study on 3-month old rats
(7). On the other hand, Verzar used 25mg procaine/ Kg bodyweight (the amount which
inhibits oxidoreduction) and did not notice any modification (8). In order the solve these
contradictory results, Aslan initiated a study on 1800 white rats treated with
Gerovital-H3 (9). The results pointed out an improved general tropicity, an increased
resistance to pulmonary disease and less myocardial modifications. Fewer spontaneous
tumours occurred in the treated group as compared against the controls.
Gerovital-H3 action upon the lipid
mechanism is reflected by the lypotrope, heparinoid and lypoconverting chanracteristic
(10). Aslans procaine-based product exerts its effects on the atherogenesis process
by several mechanisms;
Gerovital-H3 diminishes the level of
plasmatic lipoproteins and lipids.
Gerovital-H3 exerts an effect on the
erythrocyte membrane (an increase in membrane fludity and a protection against osmotic
hemolisis).
Gerovital-H3 has an anti-oxidant
mechanism that reduces the oxidative stress exerted on the membrane structure. Russu et
col. Found that Gerovital-H3 exerts an inhibition on the generation of the superoxide
radical in a non-enzymatic system (11).
It has been shown that Gerovital-H3 action
on the lipid metabolism results in modifications in the serum total cholesterol, changes
of the lipoprotein fractions ratio and changes to the unsaturated fatty acids content
(11).
The international confirmations
Mention must be made of the fact that the
research concerning Gerovital-H3 therapy has been simulated in over 500 medical and
scientific publications.
The experiements utilsiling the original
Aslan product and method confirm the efficiency and efficacy of Gerovital-H3.
The data presented at the 10th Congress of
the International Association of Gerontology in Jerusalem in 1975, and at the European
Congress of Clinical Gerontogy in 1977, made available new evidence of the efficiency of
Gerovital-H3.
The work of the special session at the
Jerusaeum Congress regarding old age pharmacology were dominated by the reseach focussed
upon the mechanism of Gerovital-H3 action .
A special interest was generated by the
mechanism of Gerovital-H3s action, particularly from several American scientists who
presented papers of double-blind placebo controlled trials.
Among them was Professor William Zung from
Duke University, North Carolina who in his study applied the treatment for 28 days on his
patients who were suffering from depression (12).
One group of patients aged 60 were
submitted before, during and after the treatment to a battery of psychological tests.
Professor Zung, a well known and respected author of psychological tests, proved the
Gerovital-H3 efficiency in the treatment of depression.
Within the same session, the American
authors, M. Kurland and M. Hayman from Palm Springs, California, presented the
double-blind results performed with Gerovital-H3 on 63 patients suffering from depression
and aged 45 to 80 (33 using Gerovital-H3 and 30 using placebo). Under observation there
were several types of depression; manic-depression, reactive depression, organic cerebral
depression, chronic reactive depression and alcoholic depression.
The results proved that Gerovital-H3
efficiency in all the tests applied, the differences between the two groups showed a great
statistical significance (p>0.001).
Particularly valuble results were
communicated by McFarlane M.D. who proved that Gerovital-H3 inhibits MAO (13). It is a
known fact that the MAO levels increase with advancing age (14). McFarlane certifies the
lack of any adverse reactions with Gerovital-H3 and he also confirmed that Gerovital-H3 is
a reversible and competitive MAO inhibitor.
The success enjoyed by Gerovital-H3 at the
Jerusaem International Congress in June 1975, was remarked upon by Professor Nathan Shock
(USA) in the closing speech of the Congress. That recognition came shortly after another
world-wide known gerontologist, Alex Comfort (England), in an article published in the
magazine "Mechanism of Ageing and Development", where he made positive remarks
upon Gerovital-H3 and Aslans method.
On the occasion of the International
meeting "Medizinischewoche" in Baden Baden, Germany in November 1983, whilst
concluding the Gerontology and Geriatrics section, Professor Paul Luth said "The
Aslan method and treatment represent the most efficient therapeutic producure in
Geriatrics." (15)
Aslans method of prophylactic and
curative treatment with Gerovital-H3
As a medical professor from 1947 to 1949,
Ana Aslan was inspired by the works of Lorich. Aslan started administering procaine in
cases of arthritis and in trophic troubles of the extremities with sometimes spectacular
results (1).
This is what Ana Aslan declared from the
very beginning; "After one injection in the femural artery given to a patient with
embolism at the level of the inferior extremity, I noticed the almost instantaneous
disappearance of pain. Then, for the first time, I had the idea of applying the same
method in certain diseases with acute pain, which produce immobilization and thus
long-lasting work incapacity."
Like other great discoveries, the clinical
observation facts did not fail Aslan, as they represented the beginning of a period of
original and fundamental studies which contributed to the prophylaxis and treatment of
aging and chronic disease. Thus, in that period, another clinical observation was pointed
out by the patients who stated that after the injections (given into the artery of the
extremities), pain was relieved in all the body. "I believe, a general effect was
obtained," concluded Aslan.
Starting in 1949, Aslan began applying her
treatment in a nursing home. Besides an improvement of the local phenomena, she noticed
that the physical and psychical state of the old men was becoming better. That was the
time when Aslan initiated experimental research which had particularly favourable effects
on all the treated animals.
I want to emphasize that, besides
introducing the procaine treatment against the aging process and degenerative illnesses
Aslan had other original contributions lying at the base of the treatment and method
bearing her name.
Aslan introduced long-term procaine
therapy.
Aslan used procaine in intramuscular
injections according to her own schedule, which represented a true therapeutic novelty,
since previously procaine had only been used for local anaesthesia, or in short-term cures
injected either subcutaneously, intravenously or, more rarely, intra-arterially.
The special moment arrived when procaine
was prepared to the new formula now known as Gerovital-H3. This is more active and has
practically no side effects if administered in therapeutic doses.
Gerovital-H3 was experimented with at the
Institute of Gerontogy and Geriatrics in Bucharest, between 1951 and 1958. In 1957, Aslan
started comparitive investigations to establish the effectiveness of the oral treatment.
To achieve the same results like in the parentral treatment, the oral dose has to be
doubled.
I must also state that at the Bucharest
Institute, to evaluate the effects of Gerovital-H3 treatment, since 1952, a clinical study
has been initiated. This study, due to the thousands of patients observed over a 25 year
time scale makes this clinical study unique in the world.
Gerovital-H3 is a complex drug acting like
the procaine molecule with its two hidrolisis products; PABA and DEAE. The addition of
benzoic acid, potassium and disodium phosphate increase the effects of Gerovital-H3
biotrophic treatment.
Indications for Gerovital-H3
Gerovital-H3 is indicated for people older
than 40 years in order to retard the aging process and as a preventative and curative
treatment for chronic degenerative diseases. Gerovital-H3 has been shown to be efficacous
in all the following ;
moderate and light depressive states.
in troubles concerning attention,
concentrating, cognitive processes and in balancing the neurovegative distinies.
chronic fatique syndrome.
sleep disorders.
tegument distrophias, trophic ulcers,
atonic wounds.
osteoarthritis, degenerating
rheumatism, osteoporosis and during fracture consolidation periods.
sexual management and improving sex
drive
Gerovital-H3 is an active
anti-aterogenous factor and recommended in cerebral and peripheral artherosclerosis and in
the treatment of post-infarct and hemiplegia consequences.
Parkinson and Parkinson syndromes.
Gerovital-H3 ameliorates the hair
resistance and quality, repigmentation, reduces the allpecia (hair loss), head skin
seborrgoea and helps eliminate the pruritus.
due to the inhibition on the
generation of the superoxide radical, Gerovital-H3 is a powerful antioxidant, a free
radical quencer.
Outcome of Gerovital-H3 treatment
Aslans treatment produces a general
transformation of the organism manifested as follows;
desire to be active and to live,
better memory, enhanced concentration ability and attention, improved optimism.
improved affective tone and psychic
and vegatative balance.
increased self-caring abilities and
exercise capacity.
more ability to cope with the
environment and increased resistance to infections.
balanced endocrine functions with
oestrogens reappearance and androgen reactivation.
improved visual, auditive and
olphactive acuity.
diminished extrapyramidal rigidity,
improved gait and increased mobility.
better skin, nails and mucous
trophicity.
hair growth stimulation with a
tendency to repigmentate the hair and a more trophic aspect.
better blood vessel reactivity.
the alleviation should also be
mentioned of the clinical symptoms of the chronic diseases; chronic rheumatism,
atherosclerosis, bronchial asthma, psoriasis, vitiligo, varicose ulcers.
improves the quality of life
retarding the rhythm of aging and preventing the chronic diseases.
improves the sex drive.
Administering method for Gerovital-H3
The long term treatment with Gerovital-H3
has been extensively established with Aslan et col. For over 40 years at the National
Institute of Gerontogoy and Geriatrics in Romania, in compliance with Aslans
methods.
At the beginning, Gerovital-H3 was
administered only as injections. The tolerance has always been tested before starting the
treatment; one subcuteneous injection of 1ml on the first day, followed by an
intramuscular injection of 2ml the next day.
If no local or general reactions occur,
proper treatment can be started. In the experience of more than 300,000 patinets that
completed this treatment in Romania, an intolerance only occurred in 1 in 7000 cases.
In 1957, Aslan started clinical and
experimental comparative investigations in order to establish the effectiveness of the
oral administration.
The dose of active substances had to be
doubled to achieve the same results as in the parenteral treatment. Considering this fact
and the difficulty raised by the accurate management in certain patients, Aslan
established a combined schedule made up of both oral and parenteral approaches as follows;
PREVENTATIVE Treatment
of chronic diseases and aging consists of 4 courses of 12 injections and 4 courses of 24
pills, ie, one course of 12 injections over 4 weeks (ie, 3 injections per week), a 4-week
break then one course of 24 pills over 12 days (one pill twice daily between meals), a
2-week break and then the cycle is resumed.
Starting from the age of 40 years,
the prophylactic treatment with pills only is recommended in a series of 25 tablets during
the first 12 days, with an interval of 2 months;
1st day, 1 tablet/ day, 2-hours after
breakfast, increasing to the 12th day when 2 tablets per day are taken, (again 2-hours
after meals, for example one at 10AM and another at 4PM).
There should a series of 5 treatment
courses in the year, which should be increased to 6 per year for persons over the age of
65.
CURATIVE Treatment in chronic
diseases requires 6 course of 12 injections, and 5 courses of 24 pills, yearly, ie, one
course of 12 injections over 4 weeks, a 2-week break, one course of 24 pills over 12 days
(one pill twice daily between the meals); 2 week break. The cycle is then resumed.
Depending upon the outcomes the physician
and patients can either shorten or extend the breaks. The first and second course of
injections can be administered daily in order to study the individual reactivity.
Gerovital-H3 treatment can be
individualised according to the disease/ diseases accompanying the aging and the patients
biological age.
In arteritis, actively influenced by
Gerovital-H3, the route of administration is intra-arterial. Aslan recommended the
intra-arterial route in arthrosis and arthritis, especially when the knee joint is
involved, and the intravenous route for cerebral spasms.
Contraindications
Gerovital-H3 should be avoided by anyone
suffering or utilising the following;
allergy or sensitivity to
Gerovital-H3 (or Novocain).
Gerovital-H3 cannot be used together
with eserine or prostigmine.
Gerovital-H3 can not be used at the
same time as sulphamides.
Gerovital-H3 should not be used with
an antibacterial treatment.
Side effects
Gerovital-H3 side effects are relatively
uncommon and may occur principally only after injections, but the frequency is very
reduced (according to the statistics there is 1 case for every 7000 patients).
The minor side effects consist of a heating
sensation and metallic taste, these effects disappear during the treatment.
The major side effects are related to the
skin; macular eruption, rash and itching which determine the interruption of the treatment
and the remake of the tolerance test (1ml injected id.) after the eruption has
disappeared. The treatment of the side effects consist of the administration of the usual
antiallergic drugs if the eruption persists after the arrest of Gervotial-H3.
In spite of its monoamineoxidase (MAO)
inhibitor character, Gerovital-H3 does not interfere, as the convential MAO inhibitors do,
with the Tyramine from food (ed.- commonly called the cheese affect), which means
there is no known incopatibility with Gerovital-H3 and food.
The interaction with sulphamides is because
of the competition on the bacterial metabolism.
Overdosage may occur only after 400mg in iv
rapid injection and the treatment is the same as for any acute intoxication.
Reference; (1). Loriche R., Lafontaine R.:
De lemploi des injections intra-arterielle de novocaine dans les formes
daouloureuses des obliterantes. Presses Medicale, 1953, 17:327.
IAS comments
We would like to thank Dr. Dumitru for
bringing up to date the monography of Gerovital-H3.
We should all be grateful to Professor Ana
Aslans work, as she helped to bring to the attention of the world the fact that
aging is a disease and like any disease it is treatable!
Even today, Gerovital-H3 remains at the
fore-front of many life-extensionists programs. This is perhaps not surprising (as Dr.
Dumitru has pointed out here) when you consider that Gerovital-H3 has such a myraid of
profound uses, both for preventative and curative purposes. This coupled with its
extremeley low toxicity and few, minor side effects means that Gerovital-H3 presents
itself as an essential, safe and very long term anti-aging supplement for those who are
serious about administering their aging condition. Look out for individualised
Gerovital-H3 articles in future issues of the IAS Anti-Aging Bulletin.
References
(1). Cohen S., Ditman K.S. Effects of
erovital-H3 on Elderly Depressive Patients. Int. Smposium of Gerontology, Bucharest, 1972.
(2). Teitel A., Gane P., Stroescu V.,
Steflea D., About the Mechanisms of Procaine. Studies of Fisiology, Bucharest, 1962, 4,
351-360.
(3). Gordon P., Fudema A., Abrams A.,
Effects of Romanian and American Procaine Preparations on Certain Physiological Aspects of
Aging. Gerontologist II, 1962, p.9, Gerontologist, 1965, 20, 2, p114-150.
(4). Ana Aslan; Gerovital-H3 Therapy in the
Prophylaxis of Ageing. Rom. J. Geront. Geriatrics. Bucharest, 1980, 1,1 p5-15.
(5). Yau M.T. Gerovital-H3,
Monoamineoxidase and Brain Monoamines. Symposium on Theoretic Aspects of Aging, 1974,
Miami, Florida.
(6). Parhon C.I., Ana Aslan, Laction
de la Vitamine H1 et H2 sur la proliferation de la cellule animale. Bull. Acad. Rom.
Bucharest, 1957, 9,1, 137.
(7). Berger P; Innocuite du traitment
chronique a la procaine chez le rat en croissance. C.R. So. Biol. 1960, 154,959.
(8). Verzar F. Note on the influence of
prcaine, PABA and DEAE on the aging of rats. Basel, 1959, Gerontology 3,6, 350-355.
(9). Ana Aslan et col. Long term treatment
with Gerovital-H3 in Albino rats. J. Gerontology, 1965, 20,1.
(10). Ana Aslan, G. Enachescu. Reseaches on
the Anti-thrombophilic activity of Gerovital-H3 treatment. Rom. J. Geront. Geriatrics,
180, 1, 2, 195-246.
(11). Russu C et col. Antioxidant and lipid
lowering effect of original procaine based product Gerovital-H3. Book of abstracts. The
16th Congress of the Internatonal Association of Gerontology, p217.
(12). Zung W.W.K., Wang H.S. Clinical
trials of Gerovital-H3 in the treatment of depression in the elderly. 10th Int. Congress
of Gerontology, 1975, Jerusalem.
(13). McFarlane M.D. Gerovital-H3 therapy;
Mechanism of inhibition ofmonoamineoxidase. J. of American Geriatrics Society., 1974,
XXII/8, p365-371.
(14). Robinson D.S. et al; Aging, monoamine
and monoamineoxidase levels, 1972, Lancet, 1, 0290.
(15). Luth P. Aslan therapie mit
Gerovital-H3. Zeitschrift fur Algemenmedizin, 1984, 60, 27, p1162-1164.
ALL INFORMATION IS EDUCATIONAL AND
SHOULD NOT REPLACE THE ADVICE OF
YOUR PHYSICIAN.
HOME
to order
International
Antiaging Systems
Les Autelets Suite A
Sark GY9 0SF
Channel Islands
Great Britain
phone: 44-870-151-4144 (Britain)
fax: 310-388-1072
(US number)
ias@smart-drugs.com
most questions can be
answered by going to FAQ
we do not accept telephone orders
we do not ship to the United Kingdom
|